Skip to main content
. 2013 Jul 18;4(7):e733. doi: 10.1038/cddis.2013.258

Figure 6.

Figure 6

(a) Western blot analysis of PARP cleavage and FLIP expression in MPM cell lines pretreated with 2.5 μM SAHA for 12 h before treatment with 10 μM AT-IAP, 10 ng/ml TNFα or a combination of AT-IAP and TNFα for 24 h. (b) Cell viability assays in REN cells pretreated with 0.5, 1, 2.5 and 5 μM SAHA for 12 h before treatment with 10 μM AT-IAP, 10 ng/ml TNFα or a combination of AT-IAP and TNFα for 48 h. (c) Caspase 3/7 activity assay in MPM cells pretreated with 2.5 μM SAHA for 12 h before treatment with 10 μM AT-IAP, 10 ng/ml TNFα or a combination of AT-IAP and TNFα for 24 h. (d) Cell viability assay in REN cells pretreated with 2.5 μM SAHA for 12 h before treatment with combinations of 100 nM or 10 nM AT-IAP with 10, 1, 0.5 or 0.1 ng/ml TNFα for 48 h